Abstract
Since the introduction of breast-conserving therapies (BCTs) in the 1970s, considerable changes have occurred in the treatment of early-stage breast cancer. Prospective studies and especially major phase III clinical trials have yielded a wealth of information, allowing us to currently achieve very high local control rates in BCT. This progress has been very well demonstrated in a few European BCT trials; each succeeding trial obtained significant higher local control rates (Fig 1). These trial results also formed a stimulus for new approaches aimed at limiting the side effects while obtaining high local control rates.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
